Erik Ostrowski - 31 Jan 2025 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: SVP, CFO, CBO & Treasurer
Signature: /s/Carolyn Rucci, attorney-in-fact for Erik Ostrowski
Issuer symbol: AKBA
Transactions as of: 31 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2025, 17:48:18 UTC
Previous filing: 02 Jul 2024
Next filing: 01 Jul 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Award	$0	+194,900	+56%	$0.000000	544,900	31 Jan 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKBA	Stock Option (Right to buy)	Award	$0	+292,300		$0.000000	292,300	31 Jan 2025	Common Stock	292,300	$2.24	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F2	The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.